Explore the words cloud of the FERTISSIMO project. It provides you a very rough idea of what is the project "FERTISSIMO" about.
The following table provides information about the project.
CARMEL DIAGNOSTICS LTD
|Coordinator Country||Israel [IL]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2016-03-01 to 2016-08-31|
Take a look of project's partnership.
|1||CARMEL DIAGNOSTICS LTD||IL (QIRYAT TIVON)||coordinator||50˙000.00|
Abstract: Carmel Diagnostics, established in 2009, is an SME that has developed clinical applications of its novel, proprietary, patented Thermochemiluminescence technology platform – TCL Analyzer™. Carmel has successfully completed “proof of concept” for its main applications: Embryo Selection in IVF process and Risk Stratification for CHF patients. The results were published in leading magazines. The technology enables assessment of Oxidative Stress in body fluids using it as a biomarker for clinical problems linked to levels of oxidative stress. TCL Analyzer is a stable, robust Point of Care system, now in its third generation. There is a huge need, clinical and economical, for novel biomarkers that will enable the physicians with effective embryo selection. With the goal of identifying embryos of high implantation probability, Carmel’s non-invasive solution will meet this need by providing a quantitative assessment of an embryo’s reproductive potential based on a biomarker - the oxidative profile of the culture media in which the embryo is incubated. This will allow the practitioner to improve pregnancy rates while reducing the incidence of multiple births. The Phase-1 project will be focused on preparing sound business plan, based on solid business model and commercialization strategy and to plan the activities for deploying the solution. This will include market and competition analysis, IP analysis, supply chain examination, risk assessment, and preparing roadmap for the clinical validation, product completion and the best route to bring the system to the market and launch it successfully. In June, 2014 Carmel won a prestigious grant of GFI - Grant for Fertility Innovation (by Merck Serono) that enabled it to build a series of improved, stable TCL Analyzer units to be used in the clinical studies. Eureka approved the project as well. Carmel’s experienced management is thrilled to build FERTISSIMO, the ultimate Embryo selection system based on TCL Analyzer.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
ENDOSCAPE, a clinically applicable non-viral gene delivery technologyRead More